We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Touchstone | LSE:IVO | London | Ordinary Share | GB00B170L953 | ORD 3 1/33P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 315.00 | 305.00 | 325.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/1/2011 09:40 | sorry XR not XF | chad0x001 | |
11/1/2011 12:43 | Why have these apparently stopped trading? has been on my watch list for a bit - am nwe to the game so not sure what XF code means. | chad0x001 | |
19/10/2010 21:38 | Imperial Innovations Group (LON:IVO) (IVO 465p/£278.03m) If you would like to have exposure to venture capital in your portfolio, but are unable to invest directly in a venture capital fund, Imperial Innovations Group (Innovations) may be the solution. Innovations has exclusive access to scientific and technological developments originating from Imperial College London and has accumulated a portfolio of more than 80 companies. Similar to venture capital firms, Innovations is able to invest at a very early stage and at very low valuations. In contrast, Innovations also benefits from having a more flexible and long term time horizon as well as additional income streams such as corporate finance and intellectual property management fees and licence and royalty revenues. Innovations recently announced preliminary results for the year ended 30 July 2010 that showed an increase in net asset value of £5.5m (or 4.4 per cent per share). Portfolio highlights included net realisations of £9.9m including £9.5m gross cash from the sale of Respivert to Centocor, representing a 4.7 times return on a three-year investment. An interesting feature of Innovations' portfolio is the long tail of revenues, even after a realisation. In addition to cash payments, the company will often receive deferred payments and this is not fully reflected in the balance sheet. Innovations' portfolio is focused on opportunities in healthcare, energy, engineering and cleantech. Several portfolio companies have very high potential and Innovations is pleased to observe excellent progress during the year. The ownership percentage in each company is typically high, which should give a "big bang for the buck" if and when successful. The high valuation does not make this a trading stock or a suitable short-term investment, however inclusion in a long-term investment portfolio such as a SIPP could provide excellent and unexpected results. | strollingmolby | |
19/10/2010 21:37 | Imperial Innovations Group (LON:IVO) (IVO 465p/£278.03m) If you would like to have exposure to venture capital in your portfolio, but are unable to invest directly in a venture capital fund, Imperial Innovations Group (Innovations) may be the solution. Innovations has exclusive access to scientific and technological developments originating from Imperial College London and has accumulated a portfolio of more than 80 companies. Similar to venture capital firms, Innovations is able to invest at a very early stage and at very low valuations. In contrast, Innovations also benefits from having a more flexible and long term time horizon as well as additional income streams such as corporate finance and intellectual property management fees and licence and royalty revenues. Innovations recently announced preliminary results for the year ended 30 July 2010 that showed an increase in net asset value of £5.5m (or 4.4 per cent per share). Portfolio highlights included net realisations of £9.9m including £9.5m gross cash from the sale of Respivert to Centocor, representing a 4.7 times return on a three-year investment. An interesting feature of Innovations' portfolio is the long tail of revenues, even after a realisation. In addition to cash payments, the company will often receive deferred payments and this is not fully reflected in the balance sheet. Innovations' portfolio is focused on opportunities in healthcare, energy, engineering and cleantech. Several portfolio companies have very high potential and Innovations is pleased to observe excellent progress during the year. The ownership percentage in each company is typically high, which should give a "big bang for the buck" if and when successful. The high valuation does not make this a trading stock or a suitable short-term investment, however inclusion in a long-term investment portfolio such as a SIPP could provide excellent and unexpected results. | strollingmolby | |
07/10/2009 15:37 | Imperial Innovations into the black | investinggarden | |
14/5/2009 18:23 | Online Stock Trades - Shares Magazine and Newspaper Stock Picks SHARES MAGAZINE Plays: Sell Barratt Developments at 160p Buy NetPlay TV at 25.75p Updates: Take profits in Sepura Hold Business Systems Group Blue Sky Stocks: Blinkx -- Lombard Medical -- Ceres Power -- Imaginatik -- Antisoma -- Synchronica -- Vyke Communications -- Falklands Oil & Gas -- Imperial Innovations !!!! -- PureCircle | jammytass | |
02/2/2009 15:49 | ceres power wins contract | jammytass | |
27/1/2009 20:01 | About Imperial Innovations Imperial Innovations combines the activities of technology transfer, company incubation and investment. Our goal is to bring valuable ideas to market either by building businesses or licensing to industry. * Imperial Innovations combines the activities of technology transfer, company incubation and investment. Our goal is to bring valuable ideas to market either by building businesses or licensing to industry. Imperial College London, consistently rated amongst the world's best universities, is our main partner and major source of ideas. We also provide a number of external research intensive organisations including both public and private sector ownership with our commercialisation services. We are highly experienced in every stage of the route to commercialisation. The services we offer include: * Technology sourcing * Intellectual property management * Commercial assessment of intellectual property * Market analysis * Licence negotiation * Incubation services and space * Investment | jammytass | |
27/1/2009 19:30 | try there web site | jammytass | |
27/1/2009 19:26 | Think you ought to put some effort into the header, explain a bit about the company perhaps... usually a good start! | and then | |
27/1/2009 18:50 | Doc jdb is one to ask about Vialogy, he has a thread on TIM. secretsqu | secretsqu | |
27/1/2009 18:47 | jammytass You're the only one here - who else is there to ask about shah talukder and Vialogy? | the_doctor | |
27/1/2009 16:24 | all the tec for the future in 1 cmpy this is a must for all tec investors | jammytass | |
15/1/2009 17:24 | on the move . much more to come | jammytass | |
15/1/2009 17:24 | on the move . much more to come | jammytass | |
17/6/2008 07:56 | after many smart investments this group will start to move very soon!!!!!!!!!!!!!!!! | jammytass | |
26/11/2007 18:35 | large stake in i2india is a great move for this group only a matter of time before they strike gold | jammytass | |
27/4/2007 15:58 | --> Hi Hyper Al, Have you invested? I've had this on my monitor ever since I came across this:- "Applied Biosystems was granted a licence by Imperial Innovations for technology which was used in the iTRAQ Reagent Kits. The iTRAQ Reagent Kit is the first set of amine-specific, stable isotope reagents that can label all peptides in up to four different biological samples simultaneously. It provides a flexible solution for quantitative biology research." Good to see a thread created. Perhaps someone will have to time to look into the company more deeply. | greynag |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions